How Many Times Revenue Does a Veterinary Practice Sell For in 2026?

Key takeaways

• No fixed revenue rule works: a veterinary practice does not reliably sell for 1× revenue or any preset percentage in 2026.
• Revenue multiple is an output: enterprise value divided by annual revenue summarizes a result after the valuation work is done.
• Normalized earnings come first: buyers apply an EBITDA multiple only after testing whether those earnings can continue under new ownership.
• Equal revenue can hide different value: doctor dependence, staffing, visits, pricing, reinvestment, and profit quality change what remains below the top line.
• The practical next step is evidence: build the EBITDA bridge and transferability case, then test both confidentially with qualified buyers.

Saturday inventory counts are blunt.

The pattern is familiar. An owner stands between pharmacy shelves and a clipboard, checking quantities after the last appointment has left.

Then comes the rumor. A neighboring practice supposedly sold for 1× revenue.

The top line is known. The earnings are not.

Nor are the seller dependence and handoff.

That omission is the valuation.

For a US companion-animal general-practice owner above $2M in annual revenue, no defensible 2026 rule says the practice sells for 1× revenue or any fixed share.

Buyers value normalized earnings and transferability before dividing enterprise value by annual revenue. The ratio comes later.

How many times revenue do veterinary practices sell for in 2026?

Not by a reliable fixed number in 2026. A revenue multiple means enterprise value divided by annual revenue.

It works best as an output, not a valuation method, after a buyer examines normalized EBITDA and the earnings likely to survive the owner’s exit. The ratio appears afterward.

I understand the question. Revenue is visible.

Easy to compare. Already printed on the statement.

Earnings take work. They require choices about owner compensation, unusual expenses, recurring costs, replacement staffing, deferred investment, and the money a buyer must spend to keep the practice’s clinical engine running after the seller leaves.

That work is exactly why a fixed revenue percentage fails.

The complete veterinary practice valuation method goes beyond this narrow question. For the times-revenue shortcut, the decisive point is simpler: top-line dollars are not equally valuable.

I use a revenue multiple only after enterprise value is supportable. At that stage, the ratio can help compare results or explain why apparently similar practices differ.

Used before the earnings work, it becomes a rumor with arithmetic attached.

Where did the 1× revenue rule come from, and what does it mean in 2026?

The 1× idea is a legacy shortcut, not a current benchmark. A November 2011 Canadian paper using 2010 companion-animal data reported value near 46% of gross revenue and said 1 year’s gross was rare.

Not a defensible current US benchmark.

That historical paper matters because it shows how long owners have repeated revenue rules. Even then, the author pushed the analysis back toward profit after fair owner and associate wages.

The Canadian setting matters. So does the age of the evidence.

The paper drew on a 2010 Canadian companion-animal survey and appeared in November 2011. I would not translate its 46% figure into a current US target, floor, or negotiating anchor.

It is history, nothing more.

The useful lesson is not the percentage. It is that a revenue rumor was already failing owners before today’s buyer market, staffing pressure, and diligence standards took shape.

A shortcut survives because it is memorable. Valuation survives because the underlying earnings can be defended.

Why does normalized EBITDA replace revenue in veterinary valuation in 2026?

Normalized EBITDA means earnings before interest, taxes, depreciation, and amortization after defensible normalizing adjustments, and it replaces the revenue shortcut because buyers pay for transferable earnings, not every dollar collected in the top line.

An EBITDA multiple applies that figure to estimate enterprise value.

An add-back is a defensible adjustment for an expense or item that will not continue in the same form after a sale. That is a definition, not permission to remove every inconvenient cost.

The full veterinary EBITDA add-backs guide owns the detailed normalization work. Here, the key is that normalized EBITDA must still reflect the people and resources required to run the practice.

A 2019 veterinary trade article put the principle bluntly: low-profit practices have low values. It named outdated pricing, high cost of goods, excessive payroll, facility limits, culture, and staff retention as possible causes.

Some are fixable. Others remain real operating risks.

That difference sits below revenue, which is why the top line cannot carry the valuation alone.

Current multiple commentary reinforces the point, although the published estimates disagree.

Octus described practice-level acquisitions in the mid-to-high single digits. QuantPillar published an 8×–14× veterinary EBITDA range from a methodology synthesizing more than 900 private transactions, yet it published no veterinary revenue-multiple table.

iVET360’s operator-side commentary said high-performing practices often sell for 8×–13× EBITDA. These are all EBITDA observations, none is a universal answer, and the lower Octus evidence cannot be edited out of the picture.

When sources disagree that widely, I do not pick the largest number. I ask which practice facts, earnings evidence, and buyer process support the actual result.

How can 2 $3M veterinary practices produce 1× and 2× implied revenue multiples in 2026?

Identical revenue can hide different earnings. In purely illustrative math, 2 artificial $3M practices with different normalized EBITDA, both assigned the same assumed 10× multiplier, produce different enterprise values and different implied EV/Revenue ratios.

The ratio follows the math. It does not create value.

The example below is purely illustrative math. Every input is artificial; it is not a market forecast, appraisal, margin benchmark, recommendation, or claim about a typical veterinary practice.

Artificial input or output	Practice A	Practice B
Annual revenue	$3M	$3M
Normalized EBITDA	$300K	$600K
Assumed multiplier	10×	10×
Implied enterprise value	$3M	$6M
Implied EV/Revenue	1×	2×

Immediately after the math, the warning bears repeating: 10% and 20% are not stated as normal margins, 10× is not recommended, and neither $3M nor $6M is a valuation forecast.

The arithmetic only proves that identical revenue can produce different implied ratios when earnings differ.

Suppose Practice A needs more owner production, more recruiting, or overdue reinvestment to preserve its revenue. Those needs can change the earnings that transfer even before anyone debates a multiple.

Practice B’s stronger artificial EBITDA does not make its ratio a rule for other owners. It merely shows how an enterprise value built from earnings can look different when divided by the same revenue denominator.

This is also where owners can confuse enterprise value with cash in their pocket. The example calculates enterprise value, not net proceeds.

Debt, cash, taxes, transaction-specific adjustments, and other closing economics sit on the bridge from enterprise value to the owner’s actual outcome.

What do revenue multiple, EBITDA multiple, and enterprise value each mean in 2026?

A revenue multiple summarizes enterprise value against revenue, while an EBITDA multiple links enterprise value to normalized operating earnings; enterprise value itself measures practice operations before cash, debt, taxes, transaction-specific adjustments, and other closing economics.

None is the owner’s net check.

Measure	Plain meaning	What it answers	What it misses
Revenue multiple	Enterprise value ÷ revenue	How value compares with sales	Earnings quality and transferability
EBITDA multiple	Enterprise value ÷ normalized EBITDA	How value compares with operating earnings	Net proceeds and transaction structure
Enterprise value	Value of practice operations	What the operating asset is worth	The owner’s after-closing outcome

One more term helps: implied EV/Revenue is the revenue multiple calculated after enterprise value has been estimated. “Implied” matters because the ratio is derived from the answer.

It is not the engine that produced the answer.

I use the revenue ratio as a diagnostic. If it looks unusually high or low, I go back to the normalized EBITDA, the multiplier, and the practice evidence rather than declaring a new market rule.

That keeps the order of operations honest.

What do broad pet-sector revenue multiples actually tell a veterinary owner in 2026?

Broad pet-sector medians show reported revenue ratios vary across samples and buyer types, while their underlying data mix food, products, services, and larger disclosed transactions, so they cannot establish a veterinary-practice rule.

Use them for market direction, not appraisal, in 2026.

R.L. Hulett’s Q4 2025 pet-sector update makes the scope problem visible.

Its reported private-equity EV/Revenue median moved to 0.7× in 2025 from 3.2× in 2024.

The reported strategic median moved to 2.7× from 2.1×.

In the same report, EV/EBITDA medians shifted to 9.9× from 16.8× for private-equity deals and to 8.1× from 13.0× for strategic deals.

Those are reported medians from a broad pet-sector deal sample, not current US veterinary-practice revenue multiples. Food, products, services, veterinary care, larger transactions, and limited disclosed-multiple samples sit inside the same report.

The update counted 8 reported veterinary-care deals in Q4 2025. That helps describe activity, but it cannot turn the sector medians into an appraisal for one companion-animal general practice.

The variation is the lesson. A revenue ratio moves when deal mix, disclosed samples, buyer type, earnings, and transaction scale move.

It does not become more precise merely because it carries a decimal.

Why is revenue alone less reliable for veterinary practices in 2026?

Revenue can rise while visits soften or pricing carries more of the growth, so the top line alone says less about durability.

In 2026, buyers need the operating story underneath revenue: doctor capacity, staffing, repeatable demand, required reinvestment, and the earnings left after normalization. That evidence separates growth from strain.

AVMA reported that visits declined roughly 3% in 2025 while revenue increased about 2.5%, with growth increasingly driven by higher prices rather than patient volume.

Only 32% of respondents said profitability improved, the lowest level in several years. Revenue movement alone did not answer the profit question.

iVET360’s April 2026 benchmark announcement told a similar story from its vendor dataset.

It reported 2.6% revenue growth in 2025, a 4.7% national decline in transaction volume, and a 7.5% rise in average transaction charge.

Those figures are vendor-reported operating signals, not universal practice economics. They still explain why a buyer separates price, volume, and profit instead of rewarding top-line growth automatically.

Scale needs context too.

AVMA’s October 2025 productivity benchmark, using 2024 practice data, put average US practice revenue near $1.5M, average revenue per veterinarian at $554,982, and average staffing at 2.76 full-time-equivalent veterinarians.

Those are profession benchmarks, not valuation inputs. They show that revenue reflects doctor capacity and operating configuration, which can differ sharply even before profit enters the conversation.

Broad deal activity also rebounded without creating a times-revenue rule. Capstone Partners reported 18 announced or completed pet transactions in 2026’s year-to-date window versus 8 in the prior-year period.

Its broad pet-sector count included 3 platform deals and 5 add-on transactions. That is useful market context, but transaction activity does not tell me what an individual veterinary practice earns or transfers.

How does a competitive process test value beyond a revenue rumor in 2026?

A competitive process does not turn a rumor into a benchmark. It tests how qualified buyers value the same normalized earnings, transferability evidence, and risk at the same time.

That comparison can reveal support one unsolicited conversation cannot establish. For a serious owner, that distinction matters.

The work starts before buyer contact. I want the normalized EBITDA bridge documented, the owner-production story clear, and the risks disclosed well enough that every serious participant evaluates the same practice.

Then the market test must stay private and disciplined.

Our Elite Selling System is built around that discipline: we hand-select and vet every buyer who gets to bid, the way a doorman with a velvet rope admits only the right people.

That is different from collecting vague opinions. Qualified buyers receive consistent evidence, work inside the same competitive window, and show what they will support under comparable conditions.

The guide to selling a veterinary practice covers the complete sale path. For this article, the narrow lesson is that a process tests evidence; a revenue rumor skips it.

When several qualified parties respond to the same earnings and transferability case, the owner gains information no single ratio can supply.

What should a veterinary owner prepare next in 2026?

Prepare a normalized EBITDA bridge, transferability evidence, and a clean record of doctor coverage, staffing, visits, pricing, and reinvestment. Then test value confidentially with qualified buyers.

Do not multiply last year’s revenue by a neighbor’s ratio and mistake the result for market evidence.

Transferability means the likelihood that earnings, staff, clients, and operating routines continue under new ownership. Buyers cannot see it from a revenue total.

They need doctor-production detail, associate stability, management coverage, visit and pricing trends, recurring costs, and a credible view of what the practice must spend next.

I would prepare the bridge before accepting anyone’s headline number. It gives every later conversation a common financial starting point and exposes weak assumptions while the owner still has time to address them.

The next useful move is not another rumor. It is an evidence-backed, confidential market test.

If you want that starting point, request a free, confidential practice value estimate. We will examine the earnings beneath the revenue and show which questions still need answers before a serious process.

The ratio can wait. Your life’s work deserves better than a shortcut.

---

Frequently asked questions from veterinary owners in 2026

Do veterinary practices sell for 1× revenue in 2026?

Not by a reliable rule.

After enterprise value is established, a veterinary practice may produce an implied ratio near, below, or above 1×, but buyers reach that result only after examining normalized EBITDA, transferability, doctor coverage, and risk.

What is a veterinary practice revenue multiple in 2026?

It is a summary ratio.

A revenue multiple divides enterprise value by annual revenue after valuation work, and 2 practices with equal revenue can produce different implied ratios because the normalized earnings underneath them differ.

Why do veterinary buyers use EBITDA instead of revenue in 2026?

Revenue is only the top line.

Buyers use normalized EBITDA because revenue can hide staffing costs, doctor dependence, required reinvestment, or weak profitability; after establishing enterprise value from earnings evidence, they can divide it by revenue for comparison.

What is normalized EBITDA for a veterinary practice in 2026?

Normalization must survive scrutiny.

Normalized EBITDA is earnings before interest, taxes, depreciation, and amortization after defensible adjustments, including any add-back for an expense or item that will not continue in the same form after a sale.

Is implied EV/Revenue the same as owner proceeds in 2026?

No.

Implied EV/Revenue divides enterprise value by revenue, while owner net proceeds depend on cash, debt, taxes, transaction-specific adjustments, other closing economics, and the owner’s accounting, tax, and legal facts.

Can 2 veterinary practices with the same revenue have different values in 2026?

Yes.

Equal revenue can sit above different normalized earnings, doctor capacity, staffing stability, owner dependence, and reinvestment needs, changing both the enterprise value buyers support and the implied revenue multiple calculated afterward.

Do pet-sector revenue multiples set veterinary practice value in 2026?

No. Broad pet-sector reports mix food, products, services, veterinary care, deal sizes, and limited disclosed samples.

Their medians can show market direction but cannot establish a current US veterinary-practice revenue multiple or replace practice-level earnings analysis.

What should I prepare before valuing my veterinary practice in 2026?

Start with evidence.

Prepare clean financial statements, a defensible normalized EBITDA bridge, doctor-production and staffing detail, visit and pricing trends, reinvestment needs, and proof that earnings will transfer before testing the result confidentially with qualified buyers.

---

Sources

Industry M&A research and valuation data

1. Canadian Veterinary Journal. Darren Osborne. “How Much Is Your Practice Worth?” November 2011, using 2010 Canadian Veterinary Medical Association companion-animal survey data. pmc.ncbi.nlm.nih.gov
2. R.L. Hulett. “Pet M&A Update, Q4 2025.” Published February 2026. rlhulett.com
3. QuantPillar. “2025–2026 Private Market Valuation Multiples.” Updated Q1 2026. quantpillar.com
4. Octus. “Private-Credit Exposure to Veterinary Rollups.” January 16, 2026. octus.com
5. iVET360. “Understanding Your Animal Hospital’s EBITDA.” 2024-era operator commentary. ivet360.com
6. Capstone Partners. “Pet Sector M&A Update.” April 10, 2026. capstonepartners.com

Veterinary practice operations, benchmarks, and profession data

7. Today’s Veterinary Business. Leslie A. Mamalis. “Should You Buy a No-Lo Practice?” December 1, 2019. todaysveterinarybusiness.com
8. AVMA. “Veterinarians Report Increasing Price Sensitivity, Decreasing Visits.” February 13, 2026. avma.org
9. iVET360. “2026 Veterinary Industry Benchmark Report.” April 9, 2026. ivet360.com
10. AVMA. “Benchmarking Data Plus Elevating Efficiency Equals Practice Productivity.” October 15, 2025, using 2024 practice data. avma.org